Chimerix, Inc.

NasdaqGM:CMRX Stock Report

Market Cap: US$311.2m

Chimerix Management

Management criteria checks 3/4

Chimerix's CEO is Mike Andriole, appointed in Aug 2023, has a tenure of 1.33 years. total yearly compensation is $1.31M, comprised of 40.3% salary and 59.7% bonuses, including company stock and options. directly owns 0.37% of the company’s shares, worth $1.16M. The average tenure of the management team and the board of directors is 1.3 years and 5.7 years respectively.

Key information

Mike Andriole

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage40.3%
CEO tenure1.3yrs
CEO ownership0.4%
Management average tenure1.3yrs
Board average tenure5.7yrs

Recent management updates

Recent updates

Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy

Dec 11

We're Keeping An Eye On Chimerix's (NASDAQ:CMRX) Cash Burn Rate

Jul 16
We're Keeping An Eye On Chimerix's (NASDAQ:CMRX) Cash Burn Rate

Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation

Aug 23

Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

Jul 20
Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

Chimerix: Down But Not Out

Jun 06

Chimerix: Searching For Clarity

Jan 05

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Dec 24
Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Is Chimerix (NASDAQ:CMRX) A Risky Investment?

Sep 16
Is Chimerix (NASDAQ:CMRX) A Risky Investment?

Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Jun 08
Does Chimerix (NASDAQ:CMRX) Have A Healthy Balance Sheet?

Chimerix gets FDA approval for TEMBEXA for the treatment of smallpox

Jun 04

Chimerix, Inc. (NASDAQ:CMRX): Are Analysts Optimistic?

May 13
Chimerix, Inc. (NASDAQ:CMRX): Are Analysts Optimistic?

Chimerix Investor Presentation - Slideshow

May 08

Chimerix expands oncology program with acquisition of Oncoceutics, shares up 10%

Jan 08

Who Has Been Buying Chimerix, Inc. (NASDAQ:CMRX) Shares?

Jan 01
Who Has Been Buying Chimerix, Inc. (NASDAQ:CMRX) Shares?

Chimerix rises 9.1% premarket after FDA accepts NDA for smallpox countermeasure

Dec 07

Chimerix (NASDAQ:CMRX) Is In A Good Position To Deliver On Growth Plans

Dec 05
Chimerix (NASDAQ:CMRX) Is In A Good Position To Deliver On Growth Plans

CEO Compensation Analysis

How has Mike Andriole's remuneration changed compared to Chimerix's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$84m

Jun 30 2024n/an/a

-US$85m

Mar 31 2024n/an/a

-US$83m

Dec 31 2023US$1mUS$528k

-US$82m

Sep 30 2023n/an/a

-US$85m

Jun 30 2023n/an/a

US$180m

Mar 31 2023n/an/a

US$176m

Dec 31 2022US$2mUS$455k

US$172m

Sep 30 2022n/an/a

US$154m

Jun 30 2022n/an/a

-US$106m

Mar 31 2022n/an/a

-US$101m

Dec 31 2021US$2mUS$433k

-US$173m

Sep 30 2021n/an/a

-US$145m

Jun 30 2021n/an/a

-US$138m

Mar 31 2021n/an/a

-US$131m

Dec 31 2020US$960kUS$420k

-US$44m

Sep 30 2020n/an/a

-US$35m

Jun 30 2020n/an/a

-US$98m

Mar 31 2020n/an/a

-US$105m

Dec 31 2019US$1mUS$292k

-US$113m

Compensation vs Market: Mike's total compensation ($USD1.31M) is below average for companies of similar size in the US market ($USD2.13M).

Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.

CEO

Mike Andriole (51 yo)

1.3yrs

Tenure

US$1,312,421

Compensation

Mr. Michael T. Andriole, also known as Mike, is CEO, President & Director of Chimerix, Inc. since August 01, 2023 and had been the Chief Business Officer of Chimerix, Inc. since April 8, 2019 until August...

Leadership Team

NamePositionTenureCompensationOwnership
Michael Andriole
CEO, President & Director1.3yrsUS$1.31m0.37%
$ 1.2m
Michael Alrutz
Senior VP10.3yrsUS$793.85k0.15%
$ 458.7k
Allen Melemed
Chief Medical Officer4.5yrsUS$931.79k0.062%
$ 191.9k
Michelle LaSpaluto
Chief Financial Officerless than a yearno data0.12%
$ 384.1k
Thomas Riga
Chief Operating & Commercial Officer1.1yrsno datano data
David Jakeman
Vice President of Accounting & Finance5.5yrsno data0.12%
$ 380.4k
Joshua Allen
Chief Scientific Officerless than a yearno datano data
Roy Ware
Chief Manufacturing Technology Officer1.2yrsno datano data

1.3yrs

Average Tenure

50.5yo

Average Age

Experienced Management: CMRX's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Michael Andriole
CEO, President & Director1.3yrsUS$1.31m0.37%
$ 1.2m
Fred Middleton
Independent Director6.8yrsUS$119.52k0.34%
$ 1.1m
Seth Rudnick
Member of Scientific Advisory Boardno datano datano data
Martha Demski
Lead Independent Director19.9yrsUS$144.52k0.080%
$ 249.3k
Michael Sherman
Chairman5.7yrsUS$1.52m0.39%
$ 1.2m
Douglas Richman
Member of Scientific Advisory Boardno datano datano data
Pratik Multani
Independent Director4.8yrsUS$104.52k0%
$ 0
Michael Boeckh
Member of Clinical Advisory Boardno datano datano data
Earl Kern
Member of Scientific Advisory Boardno datano datano data
Raymund Razonable
Member of Clinical Advisory Boardno datano datano data
Robert Meyer
Independent Director6.8yrsUS$117.02k0.039%
$ 121.6k
Victoria Vakiener
Independent Director3.7yrsUS$107.02k0%
$ 0

5.7yrs

Average Tenure

63yo

Average Age

Experienced Board: CMRX's board of directors are considered experienced (5.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 14:26
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chimerix, Inc. is covered by 22 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBarclays
Jonathan AschoffBrean Capital
Ritu BaralCanaccord Genuity